Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006823 · ClinicalTrials.gov registry record
Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C
A clinical trial of Chronic Hepatitis C, sponsored by Duke University.
- Completed
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT02006823 is a study of Chronic Hepatitis C that has completed, run by Duke University. The registered enrollment target is 20 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02006823, a study of Chronic Hepatitis C, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will explore ways to improve the effectiveness of patient Self Management at a time when genetic test results guide new treatments that will dramatically increase the possibility of cure of the hepatitis C virus.The study will also focus on the interactions between provider and patients and the ways that technical work, adaptive work and adaptive leadership foster patient self-management.This proposed 2 year exploratory mixed-methods 12 longitudinal case study will explore patients' and providers' explanations for how and why they engage in technical work, adaptive work, and adaptive leadership and the ways in which these strategies promote or pose barriers to patients' self-management of Chronic Hepatitis C in the context of the new genetic test results and treatments. Specific aims are to: 1: Examine how technical work, adaptive work and adaptive leadership influence patients' perceptions of their likelihood of cure and how this work relates to self-management during 12 to 24 weeks of treatment for Chronic Hepatitis C. Research questions are: 1.1) How do patients describe their interactions with the providers? 1.2) How do these interactions shape patients' perceptions of the likelihood of cure? 1.3) How do patients' understanding of their interactions with the provider promote the use of or pose barriers to self-management during treatment? AIM 2: Describe providers' use of technical work, and adaptive leadership approaches during clinical encounters,to include nurse education visits. Research questions are: 2.1) What technical work, and adaptive leadership approaches do providers use when sharing treatment information with patients during the clinical encounters. 2.2) What explanations do providers give for how and why they use technical work and adaptive leadership approaches? AIM 3: Describe the trajectories of illness perceptions(Control/Cure sub-scale - Illness Perception Scale), symptoms (M.D. Anderson Symptom Inventory) , viral load, and self-
Conditions Studied
Study Locations (2)
North Carolina
- Duke University Medical Center - Durham
- Boice Willis Clinic - Rocky Mount
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006823
The ClinicalTrials.gov registry entry for NCT02006823 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (91% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 0 interventions.
NCT02006823 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02006823 about?
NCT02006823 is a clinical study titled "Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C". This study will explore ways to improve the effectiveness of patient Self Management at a time when genetic test results guide new treatments that will dramatically increase the possibility of cure of the hepatitis C virus.The study will also focus on the interactions between provider and patients a...
What is the current status of trial NCT02006823?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2012-03. Estimated completion is 2014-07.
What conditions does trial NCT02006823 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
Who is sponsoring clinical trial NCT02006823?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02006823 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
-
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
COMPLETED · Phase 3
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.